KRISTINA CALLIS DUFFIN portrait
  • Professor, Dermatology
801-581-6465

Research Statement

Dr Callis Duffin is the vice-chair for clinical research in the Department of Dermatology and is co-director of the Utah Psoriasis Initiative. She has conducted research on the genetics of psoriasis, participating in the first psoriasis genome-wide association studies. She has published on co-morbidities of psoriasis such as sleep apnea and obesity. She has been principal or sub-investigator on over 50 psoriasis, eczema, and other dermatology clinical trials.  She is currently leading efforts to develop core outcome sets for psoriasis trials and clinical practice. 

Research Keywords

  • Psoriasis

Presentations

  • Course Presenter & Instructor, Eli Lilly National, Psoriasis Endpoints (PASI) Training for Investigators, Chicago, IL. , , 2012.
  • Course Presenter & Instructor, Eli Lilly National, Psoriasis Endpoints (PASI) Training for Investigators, Prague, Czech Republic. , , 2012.
  • Course Presenter & Instructor, Eli Lilly National, Psoriasis Endpoints (PASI) Training for Investigators, Uncover Study RHAZ, Rome, Italy. , , 2012.
  • Course Presenter & Instructor, ApoPharma, Psoriasis Endpoints (PASI) Training for Investigators, Toronto, Ontario, Canada. , , 2011.
  • Course Presenter & Instructor, ApoPharma, Psoriasis Endpoints (PASI) Training for Investigators, Houston, TX. , , 2011.
  • Course Presenter & Instructor, Pfizer Inc., Psoriasis Endpoints (PASI) Training for Investigators, JADP phase II, Detroit, MI. , , 2011.
  • Course Presenter & Instructor, Eli Lilly National, Psoriasis Endpoints (PASI) Training for Investigators, North American Uncover RHAZ, Chicago, IL. , , 2011.
  • Course Presenter & Instructor, Eli Lilly National, Psoriasis Endpoints (PASI) Training for Investigators, Chicago, IL. , , 2010.
  • Presenter, Amgen Inc., Scalp Psoriasis Endpoints Training for Investigators (Live Recording for online presentation). , , 2009.
  • Presenter, Wyeth, Presenter, PASI instruction. , , 2008.
  • Speaker, Amgen Inc., Lecture on "Identifying and Managing Psoriatic Disease, San Antonio, Texas. , , 2008.
  • Presenter, Wyeth, PASI/PGA Teleweb Training Sessions (follow up for PRESTA Study). , , 2006.
  • Speaker, Wyeth, PASI/PGA Training Session, Wyeth Investigator Meeting, Paris, France. , , 2006.
  • Presenter, Wyeth, Investigator Meeting (PRESTA Trial), London, UK. , , 2005.
  • Presenter, Wyeth, Investigator Meeting (CLEAREST Trial), Vienna, Austria. , , 2004.
  • Presenter, Amgen Inc., Webconference Presentation, Salt Lake City, UT. , , 2004.
  • Presenter, Centocor, Inc., Imact Investigator Meeting, London, England. , , 2003.
  • Presenter, Centocor, Inc., ExPress Investigator Meeting, Ft. Lauderdale, FL. , , 2002.
  • Presenter, GlaxoSmithKline, Investigator Meeting, Philadelphia, PA. , , 2002.
  • Presenter, GlaxoSmithKline, Investigator Meeting, Las Vegas, NV. , , 2002.
  • Presenter, Immunex, 16.0042 Investigator Meeting, Amsterdam, The Netherlands. , , 2002.
  • Presenter, Immunex, 16.0039 Study Investigator's Meeting, Phoenix, AZ. , , 2002.
  • "Psoriasis - What's New", Practical Dermatology for Primary Care Conference, Salt Lake City, UT. , , 2015.
  • "Prescribing Biologics for Moderate to Severe Psoriasis. Oregon Dermatology Society, Sunriver Resort, Bend, Oregon. , , 2012.
  • "Challenging Case Studies of Psoriasis". Montana Academy of Dermatology Annual Meeting, Big Sky, MT. , , 2012.
  • "Prescribing Biologics for Psoriasis: FAQs". Montana Academy of Dermatology Annual Meeting, Big Sky, MT. , , 2012.
  • "Co-Morbidities of Psoriasis". Montana Academy of Dermatology Annual Meeting, Big Sky, MT. , , 2012.
  • "The Science of Psoriasis." Physician Assistant Summit, National Psoriasis Foundation, Orlando, FL, USA. , , 2011.
  • "Systemic Agents for Psoriasis." Physician Assistant Summit, National Psoriasis Foundation, Orlando, FL, USA. , , 2011.
  • "Burden of Psoriasis and Psoriatic Arthritis." Chief Resident's Meeting, National Psoriasis Foundation, Chicago, IL, USA. , , 2011.
  • "Psoriasis and Women's Issues." Chief Resident's Meeting, National Psoriasis Foundation, Chicago, IL, USA. , , 2011.
  • "Therapies for Psoriasis: The Research Pipeline." Idaho Rheumatology Society 2011 Annual Meeting, Twin Falls, ID. , , 2011.
  • "Topical Therapies for Psoriasis: Maximizing Treatment." Idaho Rheumatology Society 2011 Annual Meeting, Twin Falls, ID. , , 2011.
  • "Challenging Case Studies in Psoriasis." Winter Skin Seminar, Canyons Resort, Park City, UT, USA. , , 2011.
  • "Genetics of Psoriasis: Linking Genetics to the Immunology of Psoriasis." Cutaneous Biology Course for Residents in Dermatology, Indiana University, Indianapolis, IN. , , 2009.
  • "Burden of Psoriasis",Colorado Dermatologic Society, Denver, CO, USA. , , 2009.
  • "Update on the Utah Psoriasis Initiative: Genotype and Environmental Interactions in Psoriasis and Psoriatic Arthritis."Montagna Symposium on the Biology of the Skin 2008: Salishan Resort, Gleneden Beach, OR, USA. , , 2008.
  • "Psoriasiform Mythology: unraveling urban legends and controversies in psoriasis." Intermountain Dermatology Society Annual Meeting: Sun Valley, ID,USA. , , 2006.
  • "The Utah Psoriasis Initiative: applied aspects of stratification by phenotype." 8th International National Psoriasis Foundation Genetics meeting, Paris, France. , , 2005.
  • "Update on the Genetics of Psoriasis" Keynote Presentation, National Psoriasis Foundation Patient Conference, Dallas, TX, USA. , , 2009.
  • "Psoriasis Treatment Considerations Across Gender and Age Groups", Practical Dermatology for Primary Care Conference, Salt Lake City, UT. , , 2019.
  • Therapeutic Pipeline: Psoriasis. National Psoriasis Foundation, 2017 NPF Research Symposium, Chicago, IL, USA. , , 2017.
  • Research Gaps Forum 114: Delphi survey results from IDEOM. Core Domain Set for Psoriasis Clinical Trials. 2017 American Academy of Dermatology Annual Meeting, Orlando, FL USA. , , 2017.
  • Duffin KC, Coates L, Ritchlin R. "Clinical and Patient Perspectives: a 'Joint' Approach for Improving the Management of Psoriatic Arthritis." American College of Rheumatology Satellite Symposium sponsored by Pfizer, Washington, DC, USA. , , 2016.
  • "New Psoriasis Therapies: Answers to Your Questions." Society of Dermatology Physician Assistants, Las Vegas, NV, USA. , , 2016.
  • "Perspectives on Clinical Research." 2016 National Psoriasis Foundation Trainee Symposium, Portland, OR, USA. , , 2016.
  • "Science and Burden of Psoriasis". 2016 National Psoriasis Resident Meeting, Philadelphia, PA, USA. , , 2016.
  • "Emerging Psoriasis Therapies". 2016 National Psoriasis Resident Meeting, Philadelphia, PA, USA. , , 2016.
  • Research Gaps: Delphi survey results from IDEOM. Core Domain Set for Psoriasis Clinical Trials. American Academy of Dermatology 2017 Annual Meeting, Washington, DC, USA. , , 2016.
  • Research Gaps: IDEOM Psoriasis Core Measures, Medical Dermatology Society, American Academy of Dermatology, Washington, DC, USA. , , 2016.
  • "Limitations of the Physician Global Assessment: PGA x BSA, a potential alternative to PASI in clinical practice." Presented at the International Dermatology Outcome Measures Second International Meeting, Rome, Italy. , , 2014.
  • "The Microbiome, the Skin, and Psoriasis." Presented at the Utah Dermatology Society, Zion National Park, Springdale, UT. , , 2014.
  • "Update on Dermatology Video Projects" Group for Research Assessments of Psoriasis and Psoriatic Arthritis (GRAPPA) Annual Meeting, Toronto, Ontario, Canada. , , 2013.
  • "Current and Emerging Therapies for Psoriasis". National Psoriasis Foundation Reseach Symposium, Asilomar, Pacific Grove, CA, November 19, 2012. , , 2012.
  • "Genetics of Psoriasis for the Dermatology Practitioner." Oregon Dermatology Society, Sunriver Resort, Bend, Oregon. , , 2012.
  • "Update on Dermatology Projects: Physician Global Assessment." Group for Research Assessments of Psoriasis and Psoriatic Arthritis (GRAPPA) Annual Meeting, Stockholm, Sweden. , , 2012.
  • "Psoriasis and its Comorbidities." American Academy of Dermatology Internal Medicine Course, Annual AAD Meeting, New Orleans, LA. , , 2011.
  • "Burden of Disease: from Psoriasis to CAD." Presentation given to the 7th Annual Society for Dermatologic Physician Assistants Dermatology Conference, Scottsdale, AZ. , , 2009.
  • "The UPI: Psoriasis, Cardiovascular Risk, Sleep Disorder, and Genetics." Sympsosium on Macrophage Biology and Inflammatory Mechanisms of Psoriasis and Atherosclerosis, Case Western Reserve, Cleveland, OH, USA. , , 2009.
  • "Insights into the Genetics of Psoriasis", Psoriasis Symposium 331, American Academy of Dermatology 66th Annual Session, San Antonio, TX, USA. , , 2008.
  • 'Cardiovascular Risk and Methotrexate in the Treatment of Psoriasis." Cutaneous Biology Course for Residents in Dermatology, Indiana University, Indianapolis, IN, USA. , , 2007.
  • "HLA-C, IL-12, and IL-23 risk alleles and their potential biologic role in psoriasis." 56th Annual Montagna Symposium, Salishan Resort, Gleneden Beach, OR, USA. , , 2007.
  • "Review of the Genetics of Psoriasis." Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Annual Meeting, Boston, MA. , , 2007.
  • "The Utah Psoriasis Initiative: applied aspects of stratification by phenotype." 8th International National Psoriasis Foundation Genetics meeting, Paris, France. , , 2005.
  • "Case Presentation: Catastrophic Antiphospholipid Syndrome Presenting as Foot Ischemia & Multiorgan System Failure in a Patient with SLE: An Uncommon Dermatologic Emergency." Gross and Microscopic Dermatology Resisdent Symposium, 63rd American Academy of Deramtology Annual Meeting, New Orleans, LA. , , 2005.
  • "Case Presentation: Scrotal ulcers and myositis as a presentation of Behcet's syndrome." Winter Skin Seminar, Snowmass, CO. , , 2005.
  • "Case Presentation: Scrotal ulcers and myositis as a presentation of Behcet's syndrome." Intermountain Dermatology Society Annual Meeting, Sun Valley, ID. , , 2004.
  • "Case Presentation: Shoe Dermatitis from p-tert butylphenol formaldehyde resin." Winter Skin Seminar, Whistler, B.C., Canada. , , 2004.
  • "Borderline Tuberculoid Leprosy and Reversal Reaction Due to Immune Reconstitution in the setting of Human Immunodeficiency Virus Infection." Gross and Microscopic Dermatology Resident Symposium, 62nd American Academy of Deramtology Annual Meeting, Washington, D.C. , , 2004.
  • "Case Presentation of HIV+ Male with Lues Maligna", Intermountain Dermatology Society Annual Meeting, Sun Valley, ID. , , 2003.
  • "Case Presentation of HIV+ Male with Leprosy", Utah Dermatologic Society Annual Meeting, Zion National Park, UT. , , 2003.
  • "Case Presentation of Pyoderma vegetans." Intermountain Dermatology Society Annual Meeting, Sun Valley, ID. , , 2002.
  • "Case Presentation of Burt-Hogg-Dube Syndrome", Intermountain Dermatology Society Annual Meeting, Sun Valley, ID. , , 2002.
  • "Update on Psoriasis Assessment in Clinical Trials." Kristina P. Callis and Gerald G. Krueger, National Psoriasis Foundation Medical Board Advisory Meeting, Deer Valley, UT. , , 2002.
  • Invited Speaker, National Psoriasis Foundation, "More Than Skin Deep." Patient Outreach Lecture for the National Psoriasis Foundation. (yearly, 2009-2014). , , 2009.
  • Speaker, National Psoriasis Foundation, National Psoriasis Foundation Patient Outreach Program: "Review of Psoriasis and Psoriatic Arthritis, Comorbidities, New Therapies, and the Utah Psoriasis Initiative". , , 2007.
  • Woodcock J, Callis Duffin K, Zhang Y, Stoddard G, Bowen A. Prevalence of Clinical factors and outcomes associated with invasive melanoma biopsy transection. Poster session presented at International Investigative Dermatology Annual Meeting, Edinburgh, Scotland. Poster, Presented, 2013.
  • Woodcock J, Wong B,Gerald Krueger GG, Callis Duffin K. Defining minimal disease activity in psoriasis using the Psoriasis Activity and Severity Simplified (PASS) . Poster session presented at Group for Research Assessments in Psoriasis and Psoriatic Arthritisi (GRAPPA), Naples, Italy. Poster, Presented, 2012.
  • deShazo R, Stoddard G, Yeung H, Gelfand J, Callis Duffin K. Validation of the Treatment Satisfaction Questionnaire for Medications Version II in patients with moderate-to-severe psoriasis in a clinical setting. Poster session presented at Group for Research in Psoriasis Assessments in Psoriasis and Psoriatic Arthritis (GRAPPA) Annual Meeting, Stockholm, Sweden. Poster, Presented, 2012.
  • Panko J, Schrodi S, Wong B, Callis K, Matsunami N, Cargill MA, Krueger GG. Characterizing susceptibility to phenotypic variations of psoriasis by comparing allelic association signals on PSORS loci chromosomes. Poster session presented at International Psoriasis Symposium, Stockholm, Sweden. Poster, Presented, 2006.
  • Panko J, Schrodi S, Wong B, Callis K, Matsunami N, Cargill MA, Krueger GG. Characterizing susceptibility to phenotypic variations of psoriasis by comparing allelic association signals on chromosome 6. Poster session presented at Gene to Clinic Meeting, London, England. Poster, Presented, 2005.
  • Callis KP, Wong B, et al. Assessment of Itra-observer Variability and Reliability of the NPF Reference Card as a Tool to Measure Thickness of Plaques of Psoriasis. Poster session presented at 2nd Joint Meeting, International Psoriasis Symposium and European Congress on Psoriasis. Poster, Presented, 2001.

Languages

  • English, Fluent.

Publications

  • Duffin KC,Mease PJ (date unknown). Psoriasis and psoriatic arthritis educational initiatives: An update from the 2014 GRAPPA annual meeting. (pp. 1056-1058). Vol. 42. Accepted, .
  • Duffin KC, Freeny IC, Schrodi SJ, Wong B, Feng BJ, Soltani-Arabshahi R, Rakkhit T, Goldgar DE, Krueger GG (date unknown). Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking. Vol. 129, 2777-83. Accepted, .
  • Taliercio VL, Snyder AM, Biggs AM, Kean J, Hess R, Duffin KC, Cizik AM, Secrest AM (date unknown). Clinicians' perspectives on the integration of electronic patient-reported outcomes into dermatology clinics: a qualitative study. Accepted, .
  • Belman S, Walsh JA, Carroll C, Milliken M, Haaland B, Duffin KC, Krueger GG, Feng BJ (date unknown). Psoriasis Characteristics for the Early Detection of Psoriatic Arthritis. Vol. 48, 1559-1565. Accepted, .
  • Carlisle RP, Flint ND, Hopkins ZH, Eliason MJ, Duffin KC, Secrest AM (date unknown). Administrative Burden and Costs of Prior Authorizations in a Dermatology Department. Vol. 156, 1074-1078. Accepted, .
  • Strober B, van de Kerkhof PCM, Callis Duffin K, Poulin Y, Warren RB, de la Cruz C, van der Walt JM, Stolshek BS, Martin ML, de Carvalho AVE (date unknown). Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council. Vol. 20, 699-709. Accepted, .
  • Noe MH, Wan MT, Shin DB, Armstrong AW, Duffin KC, Chiesa Fuxench ZC, Kalb RE, Menter A, Simpson EL, Takeshita J, Tyring SK, Van Voorhees AS, Mehta NN, Gelfand JM (date unknown). Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. Vol. 81, 923-930. Accepted, .
  • Wong B, Machan M, Krueger GG, Callis Duffin K (date unknown). Increased Prevalence of Sleep Disorders and Medical Comorbidities in Psoriatic Arthritis Patients Compared with Patients With and Without Psoriasis. Vol. 17, 209-215. Accepted, .
  • Perez-Chada L, Taliercio VL, Gottlieb A, Van Beek M, Duffin KC, Reeder M, Merola JF, Swerlick RA (date unknown). Achieving Consensus on Patient-Reported Outcome Measures in Clinical Practice for Inflammatory Skin Disorders: On Behalf of International Dermatology Outcome Measures and the American Academy of Dermatology. Accepted, .
  • Gelfand JM, Shin DB, Duffin KC, Armstrong AW, Blauvelt A, Tyring SK, Menter A, Gottlieb S, Lockshin BN, Simpson EL, Kianifard F, Sarkar RP, Muscianisi E, Steadman J, Ahlman MA, Playford MP, Joshi AA, Dey AK, Werner TJ, Alavi A, Mehta NN (date unknown). A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). Vol. 140, 1784-1793.e2. Accepted, .
  • Feng BJ, Sun LD, Soltani-Arabshahi R, Bowcock AM, Nair RP, Stuart P, Elder JT, Schrodi SJ, Begovich AB, Abecasis GR, Zhang XJ, Callis-Duffin KP, Krueger GG, Goldgar DE (date unknown). Multiple Loci within the major histocompatibility complex confer risk of psoriasis. Vol. 5, e1000606. Accepted, .
  • Grande-Sarpa H, Callis Duffin KP, Florell SR (date unknown). Onychodystrophy and tumor-stage mycosis fungoides confined to a single digit: report of a case and review of nail findings in cutaneous T-cell lymphoma. Vol. 59, 154-7. Accepted, .
  • Taliercio V, Langner AU, Secrest AM, Duffin KC (date unknown). Research Letter Measuring quality in psoriasis: early experiences with the MIPS 410 quality measure-cross sectional study. Accepted, .
  • Callis Duffin K, Bushmakin AG, Cappelleri JC, Mallbris L, Mamolo C (date unknown). A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies. Vol. 19, 8. Accepted, .
  • Duffin KC, Bachelez H, Mease PJ, Rosen C, Garg A, Zudak E, Elkayam O, Merola JF, Chau J, Kishimoto M, Furer V, Helliwell PS (date unknown). Pustular Psoriasis and Associated Musculoskeletal Disorders. Vol. 97, 34-38. Accepted, .
  • Duffin KC, Gottlieb AB, O'Sullivan D, Gladman DD, McFarland LV (date unknown). Prologue: 2020 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Vol. 97, 1-3. Accepted, .
  • Mease PJ, Calabrese LH, Duffin KC, Haberman RH, Firmino R, Scher JU, Schick L, Winthrop K, Merola JF (date unknown). Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting. Vol. 97, 24-29. Accepted, .
  • Blauvelt A,Papp K,Gottlieb A,Jarell A,Reich K,Maari C,Gordon KB,Ferris LK,Langley RG,Tada Y,Lima RG,Elmaraghy H,Gallo G,Renda L,Park SY,Burge R,Bagel J,Vender R,Lomaga MA,Delorme I,Hong CH,Langley RL,Albrecht L,Guenther L,Maari C,Papp K,Singh Ohson KK,Barber K,Lynde C,Gupta A,Rosoph L,Gauthier JS,Gooderham M,Wasel N,Raman M,Wiseman M,Greenstein D,Jarell A,Moon C,Clark L,Jazayeri SS,Bukhalo M,Moore A,Hamilton TK,Gewirtzman A,Hazan L,Crowley J,Teller C,Zirwas M,Smith SR,Christine Lee M,Tyring S,Lee P,Dhawan S,Leonardi C,Jesus APD,McFalda W,Frankel E,Yamauchi P,Fretzin S,Serrao R,Schlesinger T,Gottlieb S,Jenkin P,Gharib R,Davis S,Nami N,Draelos ZD,Godwin L,Owen C,Landis M,Abramovits W,Sanchez-Rivera S,Van Voorhees A,Fivenson D,Kerdel F,Forman SB,Weinberg J,Gonzalez-Chavez J,Boyce B,Stein-Gold L,Hudson C,Brown C,Coggi J,Feser C,Forconi R,Johnson S,McCune M,Green L,Madkan V,Shipp DM,Gordon KB,Waibel J,Soto-Raices O,Cather J,Miller S,Scott J,Young D,Kaffenberger J,Yokum K (date unknown). A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Vol. 182, 1348-1358. Accepted, .
  • Duffin KC,Gladman DD,Goel N,Gottlieb AB (date unknown). Prologue: 2019 annual meeting of the group for research and assessment of psoriasis and psoriatic arthritis (grappa). Vol. 96, 1-3. Accepted, .
  • Coates LC,Merola JF,Grieb SM,Mease PJ,Duffin KC (date unknown). Methotrexate in psoriasis and psoriatic arthritis. Vol. 96, 31-35. Accepted, .
  • Leung YY,Tillett W,Orbai AM,Ogdie A,Eder L,Coates LC,Holland R,Antony A,Goel N,Mease PJ,Strand V,FitzGerald O,De Wit M,Lindsay CA,Duffin KC,Gladman DD (date unknown). The grappa-omeract working group: 4 prioritized domains for completing the core outcome measurement set for psoriatic arthritis 2019 updates. Vol. 96, 46-49. Accepted, .
  • Perez-Chada LM, Salame NF, Ford AR, Duffin KC, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW (date unknown). Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) Initiative. Vol. 21, 323-338. Accepted, .
  • Waxman R,Stober C,Jadon DR,Orbai AM,Chandran V,Ogdie A,Pennington SR,De Wit M,O'Sullivan D,Mease PJ,Armstrong AW,Callis Duffin K,Helliwell PS,Van Mens LJJ,Ritchlin CT,FitzGerald O (date unknown). Proceedings of the 2019 grappa collaborative research network meeting. Vol. 96, 25-30. Accepted, .
  • Leung YY, Orbai AM, Ogdie A, Coates LC, de Wit M, Callis Duffin K, Eder L, Gladman DD, Goel N, Mease PJ, Strand V, FitzGerald O, Tillett W (date unknown). The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. Vol. 95, 33-37. Accepted, .
  • Jadon DR, Chandran V, Ogdie A, Pennington SR, Stober C, Gladman DD, de Wit M, O'Sullivan D, Mease P, Armstrong AW, Callis Duffin K, Magee C, Helliwell P, Ritchlin CT, FitzGerald O (date unknown). Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting. Vol. 95, 11-19. Accepted, .
  • Callis Duffin K, Gladman DD, Gottlieb AB, Goel N (date unknown). Prologue: 2018 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Vol. 95, 1-3. Accepted, .
  • Narayanan S, Callis-Duffin K, Batten J, Agarwal N (date unknown). Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Vol. 339, 580-1. Accepted, .
  • Jordan CT, Cao L, Roberson ED, Duan S, Helms CA, Nair RP, Duffin KC, Stuart PE, Goldgar D, Hayashi G, Olfson EH, Feng BJ, Pullinger CR, Kane JP, Wise CA, Goldbach-Mansky R, Lowes MA, Peddle L, Chandran V, Liao W, Rahman P, Krueger GG, Gladman D, Elder JT, Menter A, Bowcock AM (date unknown). Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Vol. 90, 796-808. Accepted, .
  • Armstrong AW, Parsi K, Schupp CW, Mease PJ, Duffin KC (date unknown). Standardizing training for psoriasis measures: effectiveness of an online training video on Psoriasis Area and Severity Index assessment by physician and patient raters. Vol. 149, 577-82. Accepted, .
  • Gelfand JM, Wan J, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Bebo BF Jr, Troxel AB, Shin DB, Steinemann JM, Goldfarb J, Yeung H, Van Voorhees AS (date unknown). Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Vol. 148, 487-94. Accepted, .
  • Callis Duffin K, Wong B, Horn EJ, Krueger GG (date unknown). Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. Vol. 60, 604-8. Accepted, .
  • Nair RP, Ding J, Duffin KC, Helms C, Voorhees JJ, Krueger GG, Bowcock AM, Abeçasis GR, Elder JT (date unknown). Psoriasis bench to bedside: genetics meets immunology. Vol. 145, 462-4. Accepted, .
  • Kornmehl H,Callis Duffin K,Salame N,Perez-Chada LM,Singh S,Garg A,Gottlieb AB,Latella J,Merola JF,Armstrong AW (date unknown). Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM). Vol. 237, 151-157. Accepted, .
  • Walsh JA, Callis Duffin K, Krueger GG, Clegg DO (date unknown). Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis. Vol. 40, 287-93. Accepted, .
  • Callis Duffin K, Mease PJ (date unknown). Psoriasis and Psoriatic Arthritis Video Project 2010: a report from the GRAPPA annual meeting. Vol. 38, 562-3. Accepted, .
  • Taliercio V, Langner AU, Secrest AM, Duffin KC (date unknown). Assessing psoriasis severity: psychometric validation of overall physician global assessment (OPGA). Accepted, .
  • Stein Gold L,Papp K,Pariser D,Green L,Bhatia N,Sofen H,Albrecht L,Gooderham M,Chen M,Paris M,Wang Y,Callis Duffin K (date unknown). Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Vol. 86, 77-85. Accepted, .
  • Walsh JA,Callis Duffin K,Van Voorhees AS,Chakravarty SD,Fitzgerald T,Teeple A,Rowland K,Uy J,McLean RR,Malley W,Cronin A,Merola JF (date unknown). Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry. Vol. 12, 97-119. Accepted, .
  • Noe MH,Wan MT,Mostaghimi A,Gelfand JM,Agnihothri R,Armstrong AW,Bhutani T,Bridges A,Brownstone N,Butt M,Duffin KPC,Carr C,Creadore A,Deniro KL,Desai S,Dominguez AR,Duffy EK,Fairley JA,Femia A,Gudjonsson JE,Kaffenberger JA,Katz KL,Kirby JS,Le ST,Martinez E,Maverakis E,Myers B,Naik HB,Nelson CA,Ortega-Loayza AG,Plovanich ME,Rangel LK,Ravi V,Reddy VD,Saleh JZ,Sandhu JK,Shakshouk H,Shields BE,Sharif-Sidi Z,Smith J,Steahr A,Toussi A,Wanat KA,Wang B,Wei BM,Weinhammer A,Worswick SD,Yang A (date unknown). Evaluation of a Case Series of Patients with Palmoplantar Pustulosis in the United States. Vol. 158, 68-72. Accepted, .
  • Noe MH,Wan MT,Mostaghimi A,Gelfand JM,Agnihothri R,Armstrong AW,Bhutani T,Bridges A,Brownstone N,Butt M,Duffin KPC,Carr C,Creadore A,Deniro KL,Desai S,Dominguez AR,Duffy EK,Fairley JA,Femia A,Gudjonsson JE,Kaffenberger JA,Katz KL,Le ST,Martinez E,Maverakis E,Myers B,Naik HB,Nelson CA,Ortega-Loayza AG,Plovanich ME,Rangel LK,Ravi V,Reddy VD,Saleh JZ,Kirby JS,Sandhu JK,Shakshouk H,Shields BE,Sharif-Sidi Z,Smith J,Steahr A,Toussi A,Wanat KA,Wang B,Wei BM,Weinhammer A,Worswick SD,Yang A (date unknown). Evaluation of a Case Series of Patients with Generalized Pustular Psoriasis in the United States. Vol. 158, 73-78. Accepted, .
  • Callis Duffin K,Mason MA,Gordon K,Harrison RW,Crabtree MM,Guana A,Germino R,Lebwohl M (date unknown). Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry. Vol. 237, 46-55. Accepted, .
  • Perez-Chada LM, Gottlieb AB, Cohen J, Mease P, Duffin KC, Garg A, Latella J, Armstrong AW, Ogdie A, Merola JF (date unknown). Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials. Vol. 82, 54-61. Accepted, .
  • Yeung H, Wan J, Van Voorhees AS, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Brod BA, Schleicher SM, Bebo BF Jr, Shin DB, Troxel AB, Gelfand JM (date unknown). Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. Vol. 68, 64-72. Accepted, .
  • Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF Jr (date unknown). Consensus guidelines for the management of plaque psoriasis. Vol. 148, 95-102. Accepted, .
  • Romagosa R,Kerdel F,Shah N,Krueger G,Callis K (date unknown). Treatment of psoriasis with 6-thioguanine and hepatic venoocclusive disease [6]. (pp. 970-972). Vol. 47. Accepted, .
  • Leung YY, Orbai AM, Tillett W, Ogdie A, Eder L, Goel N, Hojgaard P, Holland R, Mathew AJ, Lindsay CA, Antony A, Chau J, Christensen R, Coates LC, Mease PJ, Strand V, FitzGerald O, de Wit M, Duffin KC, Gladman DD (date unknown). Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. (pp. 60-63). Vol. 97. Accepted, .
  • deShazo RA,Secrest AM,Armstrong AW,Duffin KC (date unknown). Addressing Hypertension in Patients With Psoriasis: Review and Recommendations. Accepted, .
  • Salame N, Torres J, Sandhu J, Callis Duffin K, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW (date unknown). Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM). (pp. 112-119). Vol. 234. Accepted, .